Endocrine fibroblast growth factors in domestic animals.
Domestic animals
Endocrine FGFs
FGF19
FGF21
FGF23
Fibroblast growth factors
Journal
Domestic animal endocrinology
ISSN: 1879-0054
Titre abrégé: Domest Anim Endocrinol
Pays: United States
ID NLM: 8505191
Informations de publication
Date de publication:
09 Jul 2024
09 Jul 2024
Historique:
received:
19
12
2023
revised:
28
06
2024
accepted:
09
07
2024
medline:
27
7
2024
pubmed:
27
7
2024
entrez:
26
7
2024
Statut:
aheadofprint
Résumé
Fibroblast growth factors (FGFs) are a group of structurally homologous yet functionally pleiotropic proteins. Canonical and intracellular FGFs have primarily autocrine or paracrine effects. However, the FGF19 subfamily, composed of FGF15/19, FGF21, and FGF23, act as endocrine hormones that regulate bile acid, metabolic, and phosphorus homeostasis, respectively. Current research in human and rodent models demonstrates the potential of these endocrine FGFs to target various diseases, including disorders of inherited hypophosphatemia, chronic liver disease, obesity, and insulin resistance. Many diseases targeted for therapeutic use in humans have pathophysiological overlaps in domestic animals. Despite the potential clinical and economic impact, little is known about endocrine FGFs and their signaling pathways in major domestic animal species compared with humans and laboratory animals. This review aims to describe the physiology of these endocrine FGFs, discuss their current therapeutic use, and summarize the contemporary literature regarding endocrine FGFs in domestic animals, focusing on potential future directions.
Identifiants
pubmed: 39059301
pii: S0739-7240(24)00035-3
doi: 10.1016/j.domaniend.2024.106872
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
106872Informations de copyright
Copyright © 2024. Published by Elsevier Inc.